Corindus Vascular Robotics Inc  

(Public, NYSEAMERICAN:CVRS)   Watch this stock  
Find more results for CVRS
-0.05 (-4.35%)
Real-time:   11:49AM EST
NYSEAMERICAN real-time data - Disclaimer
Currency in USD
Range 1.08 - 1.17
52 week 0.40 - 2.25
Open 1.17
Vol / Avg. 253,120.00/1.04M
Mkt cap 207.57M
P/E     -
Div/yield     -
EPS -0.24
Shares 188.70M
Beta 20.14
Inst. own 52%
Nov 15, 2017
Corindus Vascular Robotics Inc at Stifel Healthcare Conference
Nov 7, 2017
Q3 2017 Corindus Vascular Robotics Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -323.84% -1163.90%
Operating margin -323.26% -1128.68%
EBITD margin - -1103.17%
Return on average assets -88.11% -109.98%
Return on average equity -110.93% -165.73%
Employees 92 -
CDP Score - -


309 Waverley Oaks Rd Ste 105
WALTHAM, MA 02452-8451
United States - Map
+1-508-6533335 (Phone)
+1-508-2326000 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Corindus Vascular Robotics, Inc. is engaged in robotic-assisted vascular interventions. The Company's CorPath System is a medical device that brings robotic-assisted precision to radial, coronary and peripheral procedures. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System it brings robotic precision to radial and complex interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement with manual procedures. It operates through the development, marketing and sales of robotic-assisted vascular interventions segment. The CorPath System enables the robotic-assisted control of coronary guidewires and balloon/stent devices from the safety of a radiation-protected, ergonomic interventional cockpit. The CorPath System consists of two components: a bedside unit and an interventional cockpit.

Officers and directors

Jeffrey C. Lightcap Independent Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Mark J. Toland President, Chief Executive Officer, Director
Age: 46
Bio & Compensation  - Reuters
David W. Long Chief Financial Officer, Senior Vice President, Treasurer, Secretary
Age: 46
Bio & Compensation  - Reuters
John K. Bakewell Director
Age: 55
Bio & Compensation  - Reuters
Louis A Cannon M.D. Director
Bio & Compensation  - Reuters
Gerard Winkels Director
Age: 59
Bio & Compensation  - Reuters
Hillel Bachrach Independent Director
Age: 70
Bio & Compensation  - Reuters
Jeffrey Gold Independent Director
Age: 68
Bio & Compensation  - Reuters